Non-viral Systemic Delivery of SiRNA or Antisense Oligonucleotides Targeted to Jun N-terminal Kinase 1 Prevents Cellular Hypoxic Damage

Overview

Journal Drug Deliv Transl Res

Publisher Springer

Specialty Pharmacology

Date 2011 Apr 5

PMID 21461383

Citations 8

Authors

Seema Betigeri

Min Zhang

Olga Garbuzenko

Tamara Minko

Affiliations

Soon will be listed here.

Abstract

Many pathological conditions and environmental impacts lead to the development of severe tissue hypoxia that aggravates the primary disorder, provokes cell death, and limits the patient's recovery. We hypothesized that suppression of Jun N-terminal kinase 1 (JNK1) will limit tissue damage induced by severe hypoxia. To test the hypothesis, antisense oligonucleotides (ASO) or small interfering RNA (siRNA) targeted to JNK1 mRNA were incorporated or complexed with neutral or cationic liposomes, respectively, and administered systemically to mice prior to hypoxia exposure. The animals were placed in a special chamber ventilated with room air (normoxia) or a gas mixture containing 6% O(2) and 94% N(2) (hypoxia). Liposomes, ASO, and siRNA were found to accumulate in the lungs, kidney, spleen, and heart. Only trace amounts of liposomes and their payloads (ASO and siRNA) were found in the brain. The down regulation of JNK1 protein limited activation of cell death signal, apoptotic, and necrotic tissue damage under hypoxic conditions. Consequently, we were able to verify our hypothesis and provide proof of concept of a unique approach to the prevention of cellular hypoxic damage by the suppression of JNK1 signaling pathways after the efficient delivery of ASO or siRNA.

Citing Articles

Lipid-Drug Conjugates and Nanoparticles for the Cutaneous Delivery of Cannabidiol.

Zielinska A, Cano A, Andreani T, Martins-Gomes C, Silva A, Szalata M Int J Mol Sci. 2022; 23(11).

PMID: 35682847 PMC: 9180973. DOI: 10.3390/ijms23116165.

Targeted Nanotherapeutics for Respiratory Diseases: Cancer, Fibrosis, and Coronavirus.

Majumder J, Minko T Adv Ther (Weinh). 2020; 4(2):2000203.

PMID: 33173809 PMC: 7646027. DOI: 10.1002/adtp.202000203.

Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery.

Majumder J, Minko T Expert Opin Drug Deliv. 2020; 18(2):205-227.

PMID: 32969740 PMC: 7904578. DOI: 10.1080/17425247.2021.1828339.

Strategy to enhance lung cancer treatment by five essential elements: inhalation delivery, nanotechnology, tumor-receptor targeting, chemo- and gene therapy.

Garbuzenko O, Kuzmov A, Taratula O, Pine S, Minko T Theranostics. 2019; 9(26):8362-8376.

PMID: 31754402 PMC: 6857061. DOI: 10.7150/thno.39816.

Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug.

Shah V, Taratula O, Garbuzenko O, Taratula O, Rodriguez-Rodriguez L, Minko T Clin Cancer Res. 2013; 19(22):6193-204.

PMID: 24036854 PMC: 3846837. DOI: 10.1158/1078-0432.CCR-13-1536.

References

Soni V, Kohli D, Jain S . Transferrin-conjugated liposomal system for improved delivery of 5-fluorouracil to brain. J Drug Target. 2008; 16(1):73-8. DOI: 10.1080/10611860701725381. View

Carlsson Y, Leverin A, Hedtjarn M, Wang X, Mallard C, Hagberg H . Role of mixed lineage kinase inhibition in neonatal hypoxia-ischemia. Dev Neurosci. 2009; 31(5):420-6. DOI: 10.1159/000232560. View

Chihab R, Ferry C, Koziel V, Monin P, Daval J . Sequential activation of activator protein-1-related transcription factors and JNK protein kinases may contribute to apoptotic death induced by transient hypoxia in developing brain neurons. Brain Res Mol Brain Res. 1998; 63(1):105-20. DOI: 10.1016/s0169-328x(98)00266-6. View

Dharap S, Wang Y, Chandna P, Khandare J, Qiu B, Gunaseelan S . Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc Natl Acad Sci U S A. 2005; 102(36):12962-7. PMC: 1200279. DOI: 10.1073/pnas.0504274102. View

Hossain M . Hypoxic-ischemic injury in neonatal brain: involvement of a novel neuronal molecule in neuronal cell death and potential target for neuroprotection. Int J Dev Neurosci. 2007; 26(1):93-101. PMC: 2350216. DOI: 10.1016/j.ijdevneu.2007.08.013. View

Hellwig-Burgel T, Stiehl D, Wagner A, Metzen E, Jelkmann W . Review: hypoxia-inducible factor-1 (HIF-1): a novel transcription factor in immune reactions. J Interferon Cytokine Res. 2005; 25(6):297-310. DOI: 10.1089/jir.2005.25.297. View

Rivera F, Costa G, Abin A, Urbanavicius J, Arruti C, Casanova G . Reduction of ischemic brain damage and increase of glutathione by a liposomal preparation of quercetin in permanent focal ischemia in rats. Neurotox Res. 2008; 13(2):105-14. DOI: 10.1007/BF03033562. View

Freiberg R, Krieg A, Giaccia A, Hammond E . Checking in on hypoxia/reoxygenation. Cell Cycle. 2006; 5(12):1304-7. DOI: 10.4161/cc.5.12.2811. View

Minko T, Stefanov A, Pozharov V . Selected contribution: Lung hypoxia: antioxidant and antiapoptotic effects of liposomal alpha-tocopherol. J Appl Physiol (1985). 2002; 93(4):1550-60; discussion 1549. DOI: 10.1152/japplphysiol.00007.2002. View

10.

Meerson F, Pozharov V, Minyailenko T . Superresistance against hypoxia after preliminary adaptation to repeated stress. J Appl Physiol (1985). 1994; 76(5):1856-61. DOI: 10.1152/jappl.1994.76.5.1856. View

11.

Kim B, Jun Yeol Choi , Kim Y, Woo H, Chung H . Reoxygenation following hypoxia activates DNA-damage checkpoint signaling pathways that suppress cell-cycle progression in cultured human lymphocytes. FEBS Lett. 2007; 581(16):3005-12. DOI: 10.1016/j.febslet.2007.05.053. View

12.

Kim J, Park J . ROS-dependent caspase-9 activation in hypoxic cell death. FEBS Lett. 2003; 549(1-3):94-8. DOI: 10.1016/s0014-5793(03)00795-6. View

13.

Portugal-Cohen M, Kohen R . Exposure of human keratinocytes to ischemia, hyperglycemia and their combination induces oxidative stress via the enzymes inducible nitric oxide synthase and xanthine oxidase. J Dermatol Sci. 2009; 55(2):82-90. DOI: 10.1016/j.jdermsci.2009.05.006. View

14.

Kothari S, Cizeau J, McMillan-Ward E, Israels S, Bailes M, Ens K . BNIP3 plays a role in hypoxic cell death in human epithelial cells that is inhibited by growth factors EGF and IGF. Oncogene. 2003; 22(30):4734-44. DOI: 10.1038/sj.onc.1206666. View

15.

Gupta B, Levchenko T, Torchilin V . TAT peptide-modified liposomes provide enhanced gene delivery to intracranial human brain tumor xenografts in nude mice. Oncol Res. 2007; 16(8):351-9. DOI: 10.3727/000000006783980946. View

16.

Pakunlu R, Wang Y, Saad M, Khandare J, Starovoytov V, Minko T . In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug. J Control Release. 2006; 114(2):153-62. DOI: 10.1016/j.jconrel.2006.06.010. View

17.

Zhao Y, Chen X, Du J . Cellular adaptation to hypoxia and p53 transcription regulation. J Zhejiang Univ Sci B. 2009; 10(5):404-10. PMC: 2676422. DOI: 10.1631/jzus.B0820293. View

18.

Ricci L, Valoti M, Sgaragli G, Frosini M . Protection by taurine of rat brain cortical slices against oxygen glucose deprivation- and reoxygenation-induced damage. Eur J Pharmacol. 2009; 621(1-3):26-32. DOI: 10.1016/j.ejphar.2009.08.017. View

19.

Betigeri S, Pakunlu R, Wang Y, Khandare J, Minko T . JNK1 as a molecular target to limit cellular mortality under hypoxia. Mol Pharm. 2006; 3(4):424-30. DOI: 10.1021/mp060014x. View

20.

Karin M . The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem. 1995; 270(28):16483-6. DOI: 10.1074/jbc.270.28.16483. View